The Medicines Co. (NASDAQ:MDCO) traded down 3.1% during mid-day trading on Wednesday . The stock traded as low as $37.25 and last traded at $37.49, with a volume of 479,276 shares changing hands. The stock had previously closed at $38.67.

Several equities research analysts recently issued reports on the stock. Cowen and Company reiterated a “buy” rating and issued a $45.00 target price on shares of The Medicines in a research note on Friday, August 5th. Citigroup Inc. reissued a “hold” rating on shares of The Medicines in a report on Tuesday, August 2nd. Zacks Investment Research raised shares of The Medicines from a “sell” rating to a “hold” rating in a report on Monday, August 1st. Guggenheim increased their price target on shares of The Medicines from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. Finally, Leerink Swann reissued a “buy” rating on shares of The Medicines in a report on Tuesday, July 19th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $47.33.

The company has a 50-day moving average of $35.95 and a 200 day moving average of $34.49. The firm’s market cap is $2.57 billion.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, July 27th. The company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.54. The firm had revenue of $54.70 million for the quarter, compared to analysts’ expectations of $41.93 million. During the same period in the previous year, the company earned ($0.65) EPS. The company’s quarterly revenue was down 26.5% on a year-over-year basis. Equities analysts predict that The Medicines Co. will post ($2.45) EPS for the current fiscal year.

In other news, CEO Clive Meanwell sold 10,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $35.00, for a total value of $350,000.00. Following the completion of the sale, the chief executive officer now directly owns 348,790 shares of the company’s stock, valued at approximately $12,207,650. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Christopher T. Cox bought 53,340 shares of the company’s stock in a transaction dated Tuesday, June 7th. The stock was bought at an average cost of $37.55 per share, with a total value of $2,002,917.00. Following the completion of the transaction, the executive vice president now owns 20,800 shares in the company, valued at approximately $781,040. The disclosure for this purchase can be found here.

Other large investors recently bought and sold shares of the company. Mutual of America Capital Management LLC boosted its stake in The Medicines by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 45,349 shares of the company’s stock valued at $1,693,000 after buying an additional 270 shares in the last quarter. US Bancorp DE boosted its stake in The Medicines by 20.1% in the fourth quarter. US Bancorp DE now owns 28,684 shares of the company’s stock valued at $1,071,000 after buying an additional 4,794 shares in the last quarter. New York State Common Retirement Fund boosted its stake in The Medicines by 13.2% in the fourth quarter. New York State Common Retirement Fund now owns 70,394 shares of the company’s stock valued at $2,629,000 after buying an additional 8,194 shares in the last quarter. Jennison Associates LLC boosted its stake in The Medicines by 2.3% in the fourth quarter. Jennison Associates LLC now owns 920,383 shares of the company’s stock valued at $34,367,000 after buying an additional 21,068 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in The Medicines by 8.5% in the fourth quarter. Principal Financial Group Inc. now owns 468,857 shares of the company’s stock valued at $17,507,000 after buying an additional 36,761 shares in the last quarter.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.